EMA — authorised 16 December 2015
- Marketing authorisation holder: Amgen Europe B.V.
- Status: approved
🇪🇺 Imlygic in European Union
EMA authorised Imlygic on 16 December 2015
Marketing authorisation
Imlygic in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is Imlygic approved in European Union?
Yes. EMA authorised it on 16 December 2015.
Who is the marketing authorisation holder for Imlygic in European Union?
Amgen Europe B.V. holds the EU marketing authorisation.